Status: Not yet recruiting
A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors
A phase 1, open-label, first-in-human study mainly aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GW01-200 tablets in participants with advanced tumors, including solid tumors and hematological malignancies.
Participants needed: 100
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Groovy Medicine (Hangzhou) Ltd.Updated: Jun 5, 2026Locations: 2
Eligibility criteria
Documented locally advanced or metastatic solid tumors or advanced hematological... [+4]
Participants with a known hypersensitivity to the investigational product(s) or... [+13]